About Protein FAM110B
Protein FAM110B (FAM110B) is a protein
from Homo sapiens identified by UniProt accession
Q8TC76, 370 residues long.
MolForge cross-references it against 0 known binders and
49 disease associations.
Target properties
| Protein name | Protein FAM110B |
| UniProt accession | Q8TC76 |
| Gene | FAM110B |
| Organism | Homo sapiens |
| Length | 370 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (49)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.27
- metabolite measurement · score 0.26
- delta-5 desaturase measurement · score 0.26
- response to polyunsaturated fatty acid supplementation · score 0.26
- refractive error measurement · score 0.20
- brain measurement · score 0.19
- emotional symptom measurement · score 0.18
- non-small cell lung carcinoma · score 0.07
- primary familial polycythemia due to EPO receptor mutation · score 0.05
- hemolytic anemia due to diphosphoglycerate mutase deficiency · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8TC76-F1 | alphafold | PREDICTED | 58.64 | — |
Amino-acid sequence (370 residues)
MPTETLQTGS MVKPVSPAGT FTSAVPLRIL NKGPDYFRRQ AEPNPKRLSA VERLEADKAK YVKSQEVINA KQEPVKPAVL AKPPVCPAAK RALGSPTLKV FGNHAKTESG VQRENLKLEI LKNIINSSEG SSSGSGHKHS SRNWPPHRSE ATDLHRHSFA ESLKVYPTQG RRSPQEGGSH VGRRLLEQSA ESFLHVSHSS SDIRKVTSVK PLKAIPCSSS APPLPPKPKI AAIASMKSPE ADPVEPACGV SRRPSLQRSK SDLSDRYFRV DADVERFFNY CGLDPEELEN LGMENFARAN SDIISLNFRS ASMISSDCEQ SQDSNSDLRN DDSANDRVPY GISAIERNAR IIKWLYSIKQ ARESQKVSHV
Explore Protein FAM110B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets